Genedx Holdings Corp Stock Performance

WGS Stock   94.78  3.54  3.88%   
The company retains a Market Volatility (i.e., Beta) of 1.72, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GeneDx Holdings will likely underperform. At this point, GeneDx Holdings Corp has a negative expected return of -0.45%. Please make sure to check out GeneDx Holdings' total risk alpha, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if GeneDx Holdings Corp performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days GeneDx Holdings Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more

Actual Historical Performance (%)

One Day Return
3.88
Five Day Return
10.29
Year To Date Return
(28.36)
Ten Year Return
(70.69)
All Time Return
(70.69)
Last Split Factor
1:33
Last Split Date
2023-05-04
1
GeneDx Holdings Corp. Given Consensus Rating of Moderate Buy by Analysts
11/25/2025
2
Disposition of 717 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3
12/01/2025
3
Disposition of tradable shares by Kevin Feeley of GeneDx Holdings at 150.75 subject to Rule 16b-3
12/18/2025
4
GeneDx Announces GenomeDx Prenatal, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
01/07/2026
5
GeneDx and Komodo Health Partner to Build the Worlds Most Complete Longitudinal Rare Disease Dataset
01/08/2026
6
GeneDx Holdings Is Down 12.2 percent After Raising 202526 Outlook And Launching GenomeDx Prenatal Has The Bull Case Changed
01/13/2026
7
GeneDx Holdings Corp. Shares Slammed 29 percent But Getting In Cheap Might Be Difficult Regardless
01/21/2026
8
Disposition of 366 shares by Kevin Feeley of GeneDx Holdings at 140.0824 subject to Rule 16b-3
01/23/2026
9
Surging AI-Driven Genetic Testing Demand Might Change The Case For Investing In GeneDx Holdings
01/29/2026
10
Disposition of 1166 shares by Bryan Dechairo of GeneDx Holdings at 100.3146 subject to Rule 16b-3
02/02/2026
11
Disposition of 100 shares by Bryan Dechairo of GeneDx Holdings at 91.92 subject to Rule 16b-3
02/04/2026
12
Is GeneDx Holdings Pricing Reflect Recent Slide And DCF Upside Potential
02/05/2026
13
CanSinoBIO at WGS 2026 Accelerating Global Access to Innovative Vaccines
02/09/2026
Begin Period Cash Flow100.7 M
Total Cashflows From Investing Activities-30.1 M

GeneDx Holdings Relative Risk vs. Return Landscape

If you would invest  13,035  in GeneDx Holdings Corp on November 13, 2025 and sell it today you would lose (3,557) from holding GeneDx Holdings Corp or give up 27.29% of portfolio value over 90 days. GeneDx Holdings Corp is generating negative expected returns assuming volatility of 4.0874% on return distribution over 90 days investment horizon. In other words, 36% of stocks are less volatile than GeneDx, and above 99% of all equities are expected to generate higher returns over the next 90 days.
  Expected Return   
       Risk  
Considering the 90-day investment horizon GeneDx Holdings is expected to under-perform the market. In addition to that, the company is 5.26 times more volatile than its market benchmark. It trades about -0.11 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

GeneDx Holdings Target Price Odds to finish over Current Price

The tendency of GeneDx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 94.78 90 days 94.78 
about 92.6
Based on a normal probability distribution, the odds of GeneDx Holdings to move above the current price in 90 days from now is about 92.6 (This GeneDx Holdings Corp probability density function shows the probability of GeneDx Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon the stock has the beta coefficient of 1.72 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, GeneDx Holdings will likely underperform. Additionally GeneDx Holdings Corp has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   GeneDx Holdings Price Density   
       Price  

Predictive Modules for GeneDx Holdings

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GeneDx Holdings Corp. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
85.9690.05104.26
Details
Intrinsic
Valuation
LowRealHigh
85.30111.98116.07
Details
6 Analysts
Consensus
LowTargetHigh
154.70170.00188.70
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.010.160.29
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as GeneDx Holdings. Your research has to be compared to or analyzed against GeneDx Holdings' peers to derive any actionable benefits. When done correctly, GeneDx Holdings' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in GeneDx Holdings Corp.

GeneDx Holdings Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. GeneDx Holdings is not an exception. The market had few large corrections towards the GeneDx Holdings' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GeneDx Holdings Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GeneDx Holdings within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.63
β
Beta against Dow Jones1.72
σ
Overall volatility
23.95
Ir
Information ratio -0.14

GeneDx Holdings Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GeneDx Holdings for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GeneDx Holdings Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
GeneDx Holdings Corp generated a negative expected return over the last 90 days
GeneDx Holdings Corp has high historical volatility and very poor performance
The company reported the last year's revenue of 305.45 M. Reported Net Loss for the year was (52.29 M) with profit before taxes, overhead, and interest of 280.11 M.
GeneDx Holdings generates negative cash flow from operations
GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures
Over 88.0% of the company outstanding shares are owned by institutional investors
Latest headline from finance.yahoo.com: CanSinoBIO at WGS 2026 Accelerating Global Access to Innovative Vaccines

GeneDx Holdings Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GeneDx Stock often depends not only on the future outlook of the current and potential GeneDx Holdings' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GeneDx Holdings' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding26.9 M
Cash And Short Term Investments141.2 M

GeneDx Holdings Fundamentals Growth

GeneDx Stock prices reflect investors' perceptions of the future prospects and financial health of GeneDx Holdings, and GeneDx Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneDx Stock performance.

About GeneDx Holdings Performance

Assessing GeneDx Holdings' fundamental ratios provides investors with valuable insights into GeneDx Holdings' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GeneDx Holdings is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 40.25  41.34 
Return On Tangible Assets(0.18)(0.19)
Return On Capital Employed(0.06)(0.06)
Return On Assets(0.11)(0.12)
Return On Equity(0.19)(0.20)

Things to note about GeneDx Holdings Corp performance evaluation

Checking the ongoing alerts about GeneDx Holdings for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeneDx Holdings Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
GeneDx Holdings Corp generated a negative expected return over the last 90 days
GeneDx Holdings Corp has high historical volatility and very poor performance
The company reported the last year's revenue of 305.45 M. Reported Net Loss for the year was (52.29 M) with profit before taxes, overhead, and interest of 280.11 M.
GeneDx Holdings generates negative cash flow from operations
GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures
Over 88.0% of the company outstanding shares are owned by institutional investors
Latest headline from finance.yahoo.com: CanSinoBIO at WGS 2026 Accelerating Global Access to Innovative Vaccines
Evaluating GeneDx Holdings' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate GeneDx Holdings' stock performance include:
  • Analyzing GeneDx Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneDx Holdings' stock is overvalued or undervalued compared to its peers.
  • Examining GeneDx Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating GeneDx Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneDx Holdings' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of GeneDx Holdings' stock. These opinions can provide insight into GeneDx Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating GeneDx Holdings' stock performance is not an exact science, and many factors can impact GeneDx Holdings' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.